C
holinesterase inhibitor (ChEI) drugs are approved for the symptomatic treatment of Alzheimer disease dementia (ADdem) and these agents (eg, donepezil, rivastigmine, galantamine) have consistently demonstrated modest improvement in cognitive outcomes. [1] [2] [3] Their utility in individuals with mild cognitive impairment due to AD (MCI-AD) 4 is uncertain, however, as efficacy at this initial stage of symptomatic AD has not been convincingly demonstrated. For example, although trials of ChEIs in persons with MCI have failed to demonstrate efficacy in primary outcome measures, some have shown benefit for secondary outcome measures. [5] [6] [7] One trial of donepezil in MCI found an initial slowing of cognitive decline in the early portion of the trial but not at its conclusion. 8 Another study of galantamine in combination with memantine (a non-ChEI) seemed to show benefit for the combination therapy, although the study was limited by small sample size (N = 232). 9 Finally, a meta-analysis concluded that there was no therapeutic benefit for ChEI use in MCI. 10 The cholinergic hypothesis, 11, 12 which serves as the rationale for ChEI therapy in AD, posits a central cholinergic deficit in AD that contributes to cognitive dysfunction. However, hippocampal and frontal cortical upregulation of choline acetyltransferase activity occurs in MCI, which may reduce the efficacy of ChEIs. 13 In contrast, another study showed protective effects of ChEIs for neurodegeneration. 14 These minimal and conflicting mechanistic studies of ChEI effects on central nervous systems processes provide an uncertain rationale for the use of ChEIs therapy in MCI.
Nonetheless, the use of ChEI in MCI individuals is prevalent in clinical practice. 15 To determine whether ChEI use benefits individuals with MCI-AD, and to ascertain what factors are associated with the use of ChEIs in such individuals, we conducted an observational study with data from the Uniform Data Set (UDS) 16 at the National Alzheimer's Coordinating Center (NACC).
METHODS

Participants
Data from the UDS are collected at annual visits and are supplemented by standardized Neuropathology (NP) Data Set (NDS) for those who had an autopsy. These data accrue from 30 actively funded National Institute on Aging Alzheimer Disease Centers (ADCs) and are maintained at NACC. Data collection at the ADCs occurs for each participant on an annual basis and includes demographics, medication history, clinical characteristics, and diagnoses, neuropsychological test performances, and neuropathological characteristics, using standardized UDS and NP forms. Data collected from September 2005 through August 2016 were included in this study. Details of the participant recruitment in the NACC sample and data collection procedures have been described previously. [16] [17] [18] Institutional review board of each institution reviewed and approved the study protocols. Written informed consent was obtained from all participants and informants of this study.
Participants who were naive to ChEI use at their initial UDS visit were included if they had ≥ 3 annual UDS visits and had a primary etiological diagnosis of MCI-AD [global Clinical Dementia Rating 19 (CDR) of 0 or 0.5] or mild ADdem (CDR of 0.5 or 1) at baseline; the mild ADdem group was included as it is recognized that symptomatic AD represents a continuum from its incipient stage (MCI-AD) through progressively severe stages. 20 Two groups were compared: ChEI users were participants who reported the use of any ChEI at any follow-up visit after the initial UDS visit and who had at least one visit subsequent to the one where ChEI use was reported, and ChEI nonusers were participants who never reported ChEI use at any UDS visit.
Demographic information (eg, sex, age, education level), past self-reported medical history (eg, stroke, diabetes), family history of cognitive impairment (first-degree family member), presence of coexisting problems assessed by clinician (eg, behavior, language) and medication use were collected at each UDS visit. All participants were evaluated using the standardized UDS clinical measures including the CDR and neuropsychological test battery. 18 Coexisting mood disorders were evaluated in both subjective self-report of depression and the participant's score on the 15-item Geriatric Depression Scale (GDS). 21 Apolipoprotein E (APOE) genotype was available for the majority of the sample (86%).
Neuropsychological Tests
The cognitive measures in the UDS neuropsychological battery 18 included Mini-Mental State Examination (MMSE) for global cognition, Wechsler Memory Scale Logical Memory-Immediate Recall and Delayed Recall for episodic memory, Wechsler Memory Scale-Revised (WMS-R) Digit Span Forward and Backward for attention, Wechsler Adult Intelligence Scale-Revised Digit Symbol and the Trail Making Test (parts A and B) for measuring processing speed and executive function, Animal and Vegetable list generation for semantic fluency, and Boston Naming Test (30 odd items) for naming. Dementia progression was measured by CDR Sum of Boxes (CDR-SB), which sums the individual scores in the 6 domains assessed by the CDR: memory, orientation, judgment, home and hobbies, community affairs, and personal care. 22 
Neuropathology
For participants in this study who died and came to autopsy (N = 283), neuropathologic data were retrieved from NACC's NDS as described in its standardized Neuropathology Form and Coding Guidebook. 23 The NDS has applied the National Institute on Aging-Alzheimer's Association (NIA-AA) Alzheimer's disease neuropathologic change (ADNC) guidelines 24 which rank AD NP changes in 3 parameters of an "ABC score": consisting of "A"-immunohistochemistry of amyloid beta plaque score, 25 "B"-neurofibrillary tangle (NFT) stage of Braak, 26 and "C"-neuritic plaque score from the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 27 However, ADNC scores were not gathered before 2014 [because "A" (Thal Phase) was not completed]. To permit an adequate sample size, and to provide some consistency with the "B" and "C" scores, we used the criteria of moderate to frequent neuritic plaques from CERAD (C) and Braak stage III-VI (B) to define AD NP.
Statistical Analyses
Using analyses of variance models or χ 2 tests, ChEI users and nonusers in both MCI-AD and mild ADdem groups were compared on age, education, sex, race, Hispanic ethnicity, presence of APOE ε4 allele, family history of cognitive impairment, and global CDR at the baseline. We also compared total number of UDS visits and presence of AD NP in individuals who had autopsy. In addition, we compared the age of onset and duration of cognitive decline as reported by the participants, clinician-assessed affected cognitive domains, presence of behavioral problems, self/ proxy-reported history of vascular risk factors, other contributing etiologies, initial GDS scores, and antidepressant and memantine use at initial visit in these groups.
In the MCI-AD group, <1% of participants had missing data for education and race but 12% were missing APOE genotypes. In the ADdem group, <2% of participants had missing data for education and race but 16% had missing APOE genotypes. The unadjusted logistic regression was used to calculate P-values. Statistical significance was based on the alpha level of 0.05.
General linear mixed effects models were used to examine the annual rate of change in the CDR-SB and the neuropsychological test outcomes in both MCI-AD and ADdem groups. Specifically, for the ChEI users, we implemented a piecewise linear growth/decline pattern over time that was linked at the initiation of the ChEI use (treated as time 0). The model then assumed the vector of 2 slopes (ie, the annual rates of the change before and after the initiation of ChEI use) and the performance at the initiation of ChEI use (the intercept) as both random and fixed effects. 28 For the ChEI nonusers, we implemented a simple random intercept and random slope model. Mean slopes were then compared before and after ChEI initiation among ChEI users in the MCI-AD and ADdem groups, and also to the slope of ChEI nonusers. Adjusted analyses were performed, controlling for baseline age, sex, education, race, presence of APOE ε4 allele, behavioral problems, and GDS score at baseline. All analyses were performed by SAS. 29 
RESULTS
Demographics and Baseline Characteristics
A total of 944 MCI-AD participants (322 ChEI users, 622 ChEI nonusers), and 1298 mild ADdem participants (932 ChEI users, 366 ChEI nonusers) met our eligibility criteria. Baseline characteristics differed in most of the measures between ChEI users and nonusers of both MCI-AD and ADdem groups (Table 1) . Compared with nonusers, ChEI users were more likely to have greater years of education, be of Caucasian race, and have at least 1 APOE ε4 allele. At the initial visit, ChEI users had better global CDR scores compared with the nonusers; however, at their first use of ChEI, ChEI users have worse global CDR scores compared with nonusers at the initial visit. ChEI users in both groups more often had a family history of dementia. In the ADdem group only, ChEI users were more likely to be younger at initial visit than nonusers.
In this sample, 283 had a neuropathologic examination ( Table 1) . The availability of NP data were similar between ChEI users and nonusers in the ADdem group, but ChEI users in the MCI-AD group more often had NP data than nonusers. In the ADdem group, ChEI users more frequently met neuropathologic criteria for AD compared with nonusers (135 cases, 86.5% in ChEI users; 54 cases, 76.1% in nonusers; P-value = 0.05).
Presence of other diagnoses potentially contributing to cognitive impairment was more prominent in the nonusers (Table 2 ); in particular, cerebrovascular disease was more likely to contribute in both MCI-AD and ADdem nonusers. Comorbid cardiovascular risk factors were also more often present in the ADdem nonusers. Compared with ChEI users, ChEI nonusers more often reported diabetes in the MCI-AD group and more often reported diabetes, stroke and cardiovascular disease in the ADdem group.
Reported symptoms and medication use related to depression did not differ between the groups (Table 2 ), but GDS scores were higher in the nonuser groups. Use of memantine, an N-Methyl-D-aspartic acid-receptor antagonist approved only for moderate to severe ADdem, was reported in a small subset of the MCI-AD participants (< 2%), and was reported more frequently among the ChEI nonusers (18.3%) than ChEI users (8.7%) in the ADdem group. Behavioral problems were reported more frequently in ChEI nonusers of ADdem group (62.8%) than ChEI users (51.9%) at their initial visit, but upon initiation of first ChEI use, both MCI-AD (47.2%) and ADdem (67.3%) group showed increased reports of behavioral problems (see Table, Supplementary Digital Content 1, http://links.lww.com/WAD/A212, which outlines additional clinical symptoms of sample).
Baseline cognitive test scores significantly differed between ChEI users and ChEI nonusers (see Table, Supplementary Digital Content 6, http://links.lww.com/WAD/A212). At the initial visit, ChEI nonusers scored worse than ChEI users on all cognitive measures in the ADdem group; ChEI nonusers in the MCI-AD group performed worse than ChEI users on Digit Span Forward and Backward and the Boston Naming Test.
Comparisons in Rates of Cognitive Decline Before and After ChEI Initiation
When we compared the rate of cognitive decline before and after the initiation of ChEI in unadjusted analyses, there was an increase in the rate of decline after the initiation of drug (see Table, Supplementary Digital Content 2, http://links.lww. com/WAD/A212, which shows results from Unadjusted annual change in scores in MCI-AD and ADdem participants) in both MCI-AD and ADdem groups. After controlling for demographic differences (eg, age, sex, education, race, APOE ε4 status), baseline cognition and symptoms (ie, presence of behavior problems, GDS score), the annual increase in CDR-SB before ChEI initiation was 0.03 (95% CI: −0.03, 0.09) in MCI-AD, which increased to 0.61 (95% CI: 0.52, 0.69) after ChEI initiation (Table 3 and Fig. 1 ). The annual decline in MMSE scores before ChEI initiation in MCI-AD was −0.09 Missing data-MCI-AD (ChEI users, never used ChEI): education (n = 1, n = 1), race (n = 3, n = 6), Hispanic ethnicity (n = 1, n = 4), APOE genotype (n = 37, n = 76) and mild AD dementia (ChEI users, never used ChEI): education (n = 6, n = 2), race (n = 18, n = 11), Hispanic ethnicity (n = 2, n = 0), APOE genotype (n = 130, n = 68).
Bold values are statistically significant at P < 0.05. *Diagnosis at time of first ChEI use among ChEI users or at initial visit for never users. †Used unadjusted logistic regression comparing ChEI users and never users. In a sensitivity analysis (see Table, Supplementary Digital Content 3, http://links.lww.com/WAD/A212, which shows results from sensitivity analysis in adjusted annual change in CDR-SB in MCI-AD and ADdem participants before and after begin taking ChEIs, restricting to 2 years before and after first ChEI use), we focused on the annual change in CDR-SB scores, restricted the analysis to 2 years before and after first ChEI use, and controlled for demographic differences (eg, age, sex, education, race, APOE ε4 status), presence of behavior problems and GDS scores. In both MCI-AD and ADdem groups, the rate of cognitive decline increased significantly after ChEI initiation, showing a similar trend compared with the main analysis.
Comparisons in Rates of Cognitive Decline Between ChEI Users and ChEI Nonusers
In both the MCI-AD and ADdem groups, compared with nonusers, ChEI users after initiation of ChEI had a faster decline after controlling for the demographics and baseline cognitive and behavioral symptoms (Table 4) . ChEI users showed faster CDR-SB progression than nonusers (MCI-AD: 0.24, 95% CI: 0.19, 0.30; ADdem: 1.27, 95% CI: 1.12, 1.43). Similar findings were observed for all of the other measures in both MCI-AD and ADdem groups except for Vegetable naming and Trail Making B in ADdem groups. However, when we compared the nonusers to ChEI users before initiation, Logical Memory Immediate, Delayed, and Animal naming showed a faster decline in ChEI users of MCI-AD groups. In ADdem groups, CDR-SB, MMSE, Boston Naming Test and Trail Making A showed slower decline than nonusers, but faster decline in Logical Memory Immediate and Delayed.
In post hoc analyses, the adjusted analyses for Tables 3  and 4 were repeated additionally controlling for age of onset of cognitive decline and history of diabetes, stroke, and cardiovascular disease, to control for additional factors that may influence differences in cognitive decline between the groups (Tables, Supplementary Digital Content 4 and 5, http://links.lww.com/WAD/A212). The overall conclusions remained unchanged.
DISCUSSION
Although ChEI drugs are the major symptomatic therapy for AD, their efficacy in MCI-AD is uncertain. Fewer than half (34%) of MCI-AD participants reported taking ChEIs, as would be expected given the lack of specific recommendations for the drug use at the MCI stage. Missing data-MCI-AD (ChEI users, never used ChEI): family history of cognitive impairment (n = 20, n = 36), stroke (n = 2, n = 1), diabetes (n = 0, n = 1), hypertension (n = 0, n = 1), hypercholesterolemia (n = 6, n = 3), cardiovascular disease (n = 1, n = 3), depression (n = 2, n = 4), depression medications (n = 4, n = 3), age of onset of cognitive decline (n = 28, n = 102); mild AD dementia (ChEI users, never used ChEI): family history of cognitive impairment (n = 89, n = 51), stroke (n = 3, n = 2), diabetes (n = 3, n = 1), hypertension (n = 6, n = 0), hypercholesterolemia (n = 8, n = 5), cardiovascular disease (n = 3, n = 2), depression (n = 9, n = 2), depression medications (n = 11, n = 8), age of onset of cognitive decline (n = 9, n = 10).
Bold values are statistically significant at P < 0.05. *Diagnosis at time of first ChEI use among ChEI users or at initial visit for never users. †Used unadjusted logistic regression comparing ChEI users and never users (analysis of normal cognition at initial visit used the Fisher exact χ 2 test). AD indicates Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia; ChEI, cholinesterase inhibitor; FTLD, frontotemporal lobar degeneration; MCI-AD, mild cognitive impairment with primary etiologic diagnosis of Alzheimer disease; NA, not applicable, not calculated; PPA, primary progressive aphasia. Bold values are statistically significant at P < 0.05. *Diagnosis at time of first ChEI use among ChEI users or at initial visit for never users. †Controlling for age, sex, education (y), race (White, African American, other), presence of ≥ 1 APOE ε4 allele, behavioral problems, Geriatric Depression Scale score at first visit reported taking ChEI.
‡Higher test score equates to a better score for all tests, except CDR-SB, Trail Making part A, Trail Making part B in which lower score is better score. AD indicates Alzheimer disease; CDR-SB, Clinical Dementia Rating Sum of Boxes; ChEI, cholinesterase inhibitor; CI, confidence interval; MCI-AD, mild cognitive impairment with primary etiologic diagnosis of Alzheimer disease. Seventy-two percent of ADdem participants reported taking ChEIs; although we did not assess reasons for not taking ChEIs, these may include personal preferences, costs, or contraindication due to side effects. In this study, we aimed to determine whether the use of ChEI drugs benefit MCI-AD individuals. We compared the rate of cognitive decline before and after the initiation of ChEIs and also compared the overall course of the decline of ChEI users and nonusers.
We found that initiation of ChEIs seemed to be associated with aggravated cognitive decline. This unexpected observation was consistent across all cognitive outcome measures used in the study in both MCI-AD and in mild ADdem. Despite demonstrated efficacy of ChEIs in mildmoderate ADdem (ie, a broader range of dementia severity), [1] [2] [3] we found significant acceleration in the rate of cognitive decline after the initiation of ChEIs in both MCI-AD and mild ADdem.
It is possible that our observations reflect the natural course of decline in ADdem and MCI-AD, the earliest symptomatic stages of AD, whereas the rate of cognitive decline is known to accelerate with disease progression. [30] [31] [32] The rate of pretreatment decline in our study is faster in ADdem group than the MCI-AD group, and the rate of decline after ChEI initiation in the MCI-AD group lies between the pretreatment decline of MCI-AD and ADdem groups, suggesting that the measured rate of cognitive decline rate in these early symptomatic groups may be affected more by inherent disease progression itself rather than by ChEI treatment.
Another possibility is that the decision to initiate ChEI therapy was made at the inflection point where a greater cognitive decline was perceived. Although the baseline cognitive test scores were comparable between ChEI users and nonusers in the MCI-AD group, and were significantly higher in the ChEI users of ADdem group (see Table, Supplementary Digital Content 6, http://links.lww.com/ WAD/A212, which shows the unadjusted mean scores at initial visit), at the time of ChEI initiation the cognitive scores of ChEI users in both the MCI-AD and ADdem groups were lower than those of nonusers at baseline (see Table, Supplementary Digital Content 7, http://links.lww. com/WAD/A212, which shows the unadjusted mean scores at first visit reporting ChEI use among ChEI users). If this greater decline was recognized by the individual's physician, it may have prompted the initiation of ChEIs in an effort to slow disease progression.
It also is possible that individuals who were not prescribed ChEIs had a perceived slower rate of progression or suspicion of non-AD etiology, hence discouraging the use of ChEIs. There were trends of the higher burden of AD pathology in ChEI users in the ADdem group (ADNP: 86.5% in ChEI users, 76.1% in nonusers; P = 0.05), which implies that nonusers of ChEI included more non-AD etiologies. Although nonsignificant, this trend was also seen in the MCI-AD group (ADNP: 72.7% in ChEI users, 65.2% in nonusers; P = 0.55). Although the neuropathologic data were drawn from small sample sizes, this suggests that nonusers more often had non-AD dementing disorders, which also may have factored into the non-use of ChEIs. In this regard, ChEI nonusers in the MCI-AD group showed improved longitudinal performance on the Logical Memory Immediate and Delayed measures, an unlikely result for the Logical Memory test 33 when the underlying disorder is AD.
However, the immediate change from the 2 years before ChEI initiation showed an average increase of 0.03 per year on CDR-SB ( We noted some use of memantine in the MCI-AD and ADdem participants despite a lack of efficacy for this drug at these early symptomatic stages. We also noted a lower rate of ChEI use in African American participants in our sample compared with Caucasians, consistent with recent Medicare data 34 showing health disparities for therapeutic interventions for African Americans.
We observed the overall slower cognitive decline of the study cohort, both in treatment and nontreatment groups compared with prior untreated cohorts. Previous cohorts from pre-ChEI era in 1990s have shown an average rate of decline of 3 points per year on the MMSE, 35 whereas observations from recent studies align with our study, showing a slow decline in ChEI treated patients. 36, 37 It may be possible that previous untreated cohorts were a mixed population of ADdem and non-ADdem, of which ADdem patients were treated, and for those who did not decline remained as the untreated cohort.
Alternatively, the patient population may have changed over the past few decades, and the change in the rate of decline may not be related to the use of ChEIs. For example, the Framingham heart studies showed a decreased incidence of dementia 38 regardless of decreased incidence of stroke, atrial fibrillation, and heart failure. This indicates the relevance of cardiovascular risk factors with dementia; although results from multimodality intervention trials have mixed findings, 39,40 improved control of major cardiovascular risk factors such as hypertension, diabetes mellitus, and hyperlipidemia may have affected the overall course of cognitive decline in general population.
Although our results appear to contradict the symptomatic benefit for ChEIs demonstrated in previous clinical trials, these trials 1-3 had a treatment duration of <52 weeks. One trial with a treatment duration of 3 years 36 showed no clear efficacy of the ChEI drug compared with the placebo arm.
A major limitation of our findings is that they derive from a retrospective cohort study. Interpretation of results is limited to possible correlations and associations. We tried to overcome this restriction by implementing models that show drug effects before and after ChEI initiation; however, the factors leading to a physician's decision with regard to drug therapy were not available for analysis and thus it is unknown whether perceived underlying disease progression triggered the initiation of ChEIs versus ChEI drugs themselves contributing to worsening cognitive decline. In addition, NP data were missing for a large majority of our sample, so that we could not restrict the study to participants with confirmed AD NP nor could we evaluate the possible effect of copathologies.
Although our study does not support the use of ChEI drugs in MCI-AD or mild ADdem, we were unable to control for various factors that may have influenced our findings. Randomized clinical trials are needed to evaluate the efficacy of ChEI use in the prodromal stage of symptomatic AD (MCI-AD and mild ADdem).
